- Cerivastatin
-
- $457.00 / 1mg
-
2025-06-17
- CAS:145599-86-6
- Min. Order:
- Purity: 99.31%
- Supply Ability: 10g
|
| | CERIVASTATIN SODIUM Basic information |
| Product Name: | CERIVASTATIN SODIUM | | Synonyms: | RIVASTATIN;sodium 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-dipropan-2-yl-pyrid in-3-yl]-3,5-dihydroxy-hept-6-enoate;LIPOBAY;BAYCOL;CERIVASTATIN NA;CERIVASTATIN, SODIUM SALT;7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-dipropan-2-yl-pyrid in-3-yl]-3,5-dihydroxy-hept-6-enoate;(3R,5S,6E)-7-[4-(p-Fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)-3-pyridyl]-3,5-dihydroxy-6-heptenoic acid | | CAS: | 145599-86-6 | | MF: | C26H34FNO5 | | MW: | 459.55 | | EINECS: | | | Product Categories: | Active Pharmaceutical Ingredients | | Mol File: | 145599-86-6.mol |  |
| | CERIVASTATIN SODIUM Chemical Properties |
| Melting point | >176oC (dec.) | | Boiling point | 646.3±55.0 °C(Predicted) | | density | 1.181±0.06 g/cm3(Predicted) | | storage temp. | Hygroscopic, -20°C Freezer, Under Inert Atmosphere | | solubility | Ethanol (Slightly), Methanol (Slightly), Water (Slightly) | | form | Solid | | pka | pKa 4.38 (H2O t=25 I=0.025) (Uncertain);5.29(H2O t=25 I=0.025) (Uncertain) | | color | White to Off-White | | Stability: | Hygroscopic | | CAS DataBase Reference | 145599-86-6(CAS DataBase Reference) | | EPA Substance Registry System | 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1- methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E)- (145599-86-6) |
| | CERIVASTATIN SODIUM Usage And Synthesis |
| Uses | assimilate cholesterol | | Definition | ChEBI: (3R,5S)-3,5-dihydroxyhept-6-enoic acid in which the (7E)-hydrogen is substituted by a 4-(4-fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)pyridin-3-yl group. Formerly used (as its sodium salt) to lower cho
esterol and prevent cardiovascular disease, it was withdrawn from the market worldwide in 2001 following reports of a severe form of muscle toxicity. | | Brand name | Baycol
(Bayer);Cholstat. | | in vivo | Cerivastatin is well absorbed, reaching maximal plasma levels in 1-3 hours following oral dosing. In the circulation, Cerivastatin is highly bound to plasma proteins (99.5%), with an elimination half-life of 2-4 hours. Cerivastatin is metabolized predominantly in the liver to three polar metabolites. Two of these metabolites are active, but to a lesser extent compared to parent drug, and the third metabolite is inactive. Plasma concentrations of all metabolites are substantially lower than those of the parent drug. Elimination of metabolites is via the urine (20-25%) and feces (66-73%), while essentially no parent compound is excreted[2]. |
| | CERIVASTATIN SODIUM Preparation Products And Raw materials |
|